Phase

California is poised to phase out sales of new gas-powered cars

California is poised to phase out sales of new gas-powered cars

Electric cars are parked at a charging station in Sacramento, Calif. Rich Pedroncelli/AP hide caption toggle caption Rich Pedroncelli/AP Electric cars are parked at a charging station in Sacramento, Calif. Rich Pedroncelli/AP SACRAMENTO, Calif. — California is poised to set a 2035 deadline for all new cars, trucks and SUVs sold in the state to …

California is poised to phase out sales of new gas-powered cars Read More »

‘Operating With Increased Intensity’: Zuckerberg Leads Meta Into Next Phase

‘Operating With Increased Intensity’: Zuckerberg Leads Meta Into Next Phase

SAN FRANCISCO — Mark Zuckerberg, the founder and chief executive of the company formerly known as Facebook, called his top lieutenants for the social network to a last-minute meeting in the San Francisco Bay Area this month. On the agenda: a “work-athon” to discuss the road map for improving the main Facebook app, including a …

‘Operating With Increased Intensity’: Zuckerberg Leads Meta Into Next Phase Read More »

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

PH94B for Acute Treatment of Social Anxiety Disorder Did Not Meet Primary Endpoint PH94B Showed a Favorable Safety and Tolerability Profile among Study Participants that was Consistent with Prior Clinical Trial Results SOUTH SAN FRANCISCO, Calif., July 22, 2022–(BUSINESS WIRE)–VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform …

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B Read More »

UPDATE -- NIO Inc. Reports Unaudited First Quarter 2022 Financial Results

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months Zetomipzomib continues to demonstrate a favorable safety and tolerability profile …

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis Read More »

Metro takes control of Silver Line extension, starting testing phase

Metro takes control of Silver Line extension, starting testing phase

Placeholder while article actions load Metro is taking control of the Silver Line extension, the transit agency announced Thursday, moving the long-delayed project a step closer to passenger service. Riders could begin boarding trains this fall if testing and safety accreditations are completed. The handover to the transit agency from the Metropolitan Washington Airports Authority, …

Metro takes control of Silver Line extension, starting testing phase Read More »

Bitcoin traders expect a ‘long consolidation’ phase now that BTC trades below $21K

Bitcoin traders expect a ‘long consolidation’ phase now that BTC trades below $21K

Crypto traders had a brief opportunity to pause and take stock of where things are on June 16 as the relentless selling that has hammered Bitcoin (BTC) and the wider market over the past week began to relent despite an ongoing sell-off in the traditional markets.  Data from Cointelegraph Markets Pro and TradingView shows that …

Bitcoin traders expect a ‘long consolidation’ phase now that BTC trades below $21K Read More »

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences, Inc. All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF) Bezuclastinib demonstrates favorable initial safety and tolerability …

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) Read More »

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

For investors and media only Issued: 10 June 2022, London UK – LSE announcement First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years …

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK Read More »